{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:03:33Z","timestamp":1793257413287,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073387"],"award-info":[{"award-number":["82073387"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877084"],"award-info":[{"award-number":["21877084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860547"],"award-info":[{"award-number":["81860547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703075"],"award-info":[{"award-number":["81703075"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902999"],"award-info":[{"award-number":["81902999"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860547"],"award-info":[{"award-number":["81860547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21671150"],"award-info":[{"award-number":["21671150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["KX0150720173382"],"award-info":[{"award-number":["KX0150720173382"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China Postdoctoral Science Foundation Special Funded Project","award":["2020T130476"],"award-info":[{"award-number":["2020T130476"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-redundant properties such as hypoxia and acidosis promote tumor metabolic adaptation and limit anti-cancer therapies. The key to the adaptation of tumor cells to hypoxia is the transcriptional and stable expression of hypoxia-inducible factor-1 alpha (HIF-1\u03b1). The phosphorylation-activated tumorigenic signal PI3K\/AKT\/mTOR advances the production of downstream HIF-1\u03b1 to adapt to tumor hypoxia. Studies have elucidated that acid favors inhibition of mTOR signal. Nonetheless, carbonic anhydrase IX (CAIX), overexpressed on membranes of hypoxia tumor cells with pH-regulatory effects, attenuates intracellular acidity, which is unfavorable for mTOR inhibition. Herein, a drug delivery nanoplatform equipped with dual PI3K\/mTOR inhibitor Dactolisib (NVP-BEZ235, BEZ235) and CAIX inhibitor 4\u2010(2\u2010aminoethyl) benzene sulfonamide (ABS) was designed to mitigate hypoxic adaptation and improve breast cancer treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ABS and PEG-NH<jats:sub>2<\/jats:sub> were successfully modified on the surface of hollow polydopamine (HPDA), while BEZ235 and Chlorin e6 (Ce6) were effectively loaded with the interior of HPDA to form HPDA-ABS\/PEG-BEZ235\/Ce6 (H-APBC) nanoparticles. The release of BEZ235 from H-APBC in acid microenvironment could mitigate PI3K\/mTOR signal and resist HIF-1\u03b1-dependent tumor hypoxia adaptation. More importantly, ABS modified on the surface of H-APBC could augment intracellular acids and enhances the mTOR inhibition. The nanoplatform combined with phototherapy inhibited orthotopic breast cancer growth while reducing spontaneous lung metastasis, angiogenesis, based on altering the microenvironment adapted to hypoxia and extracellular acidosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Taken together, compared with free BEZ235 and ABS, the nanoplatform exhibited remarkable anti-tumor efficiency, reduced hypoxia adaptation, mitigated off-tumor toxicity of BEZ235 and solved the limited bioavailability of BEZ235 caused by weak solubility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12951-022-01394-w","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T11:04:19Z","timestamp":1649761459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K\/mTOR inhibitor and resists HIF-1\u03b1-dependent tumor hypoxia adaptation"],"prefix":"10.1186","volume":"20","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhounan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4387-3445","authenticated-orcid":false,"given":"Shuo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"issue":"3","key":"1394_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10286","key":"1394_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750\u201369.","journal-title":"Lancet"},{"issue":"3","key":"1394_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment a review. JAMA J Am Med Assoc. 2019;321(3):288\u2013300.","journal-title":"JAMA J Am Med Assoc"},{"issue":"2","key":"1394_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","volume":"33","author":"Y Gong","year":"2021","unstructured":"Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33(2):51\u201364.","journal-title":"Cell Metab"},{"issue":"10","key":"1394_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrc.2016.84","volume":"16","author":"MS Nakazawa","year":"2016","unstructured":"Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat Rev Cancer. 2016;16(10):663\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1394_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/joim.12091","volume":"274","author":"H Rundqvist","year":"2013","unstructured":"Rundqvist H, Johnson RS. Tumour oxygenation: implications for breast cancer prognosis. J Intern Med. 2013;274(2):105\u201312.","journal-title":"J Intern Med"},{"issue":"2","key":"1394_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","volume":"27","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab. 2018;27(2):281\u201398.","journal-title":"Cell Metab"},{"issue":"2","key":"1394_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tcb.2017.10.006","volume":"28","author":"L Schito","year":"2018","unstructured":"Schito L, Rey S. Cell-autonomous metabolic reprogramming in hypoxia. Trends Cell Biol. 2018;28(2):128\u201342.","journal-title":"Trends Cell Biol"},{"key":"1394_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","volume":"502","author":"F Paredes","year":"2021","unstructured":"Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021;502:133\u201342.","journal-title":"Cancer Lett"},{"key":"1394_CR10","doi-asserted-by":"publisher","first-page":"103231","DOI":"10.1016\/j.critrevonc.2021.103231","volume":"159","author":"SAK Shamis","year":"2021","unstructured":"Shamis SAK, McMillan DC, Edwards J. The relationship between hypoxia-inducible factor 1 alpha (HIF-1 alpha) and patient survival in breast cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103231.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1394_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1582-4934.2009.00994.x","volume":"14","author":"J Chiche","year":"2010","unstructured":"Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med. 2010;14(4):771\u201394.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"1394_CR12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/0008-5472.CAN-18-1604","volume":"79","author":"N Rohani","year":"2019","unstructured":"Rohani N, Hao LL, Alexis MS, Joughin BA, Krismer K, Moufarrej MN, Soltis AR, Lauffenburger DA, Yaffe MB, Burge CB, Bhatia SN, Gertler FB. Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes. Cancer Res. 2019;79(8):1952\u201366.","journal-title":"Cancer Res"},{"issue":"9","key":"1394_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3110","volume":"11","author":"BA Webb","year":"2011","unstructured":"Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671\u20137.","journal-title":"Nat Rev Cancer"},{"issue":"1\u20132","key":"1394_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38(1\u20132):65\u201377.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"1394_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41416-019-0642-z","volume":"122","author":"HM Becker","year":"2020","unstructured":"Becker HM. Carbonic anhydrase IX and acid transport in cancer. Br J Cancer. 2020;122(2):157\u201367.","journal-title":"Br J Cancer"},{"issue":"12","key":"1394_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00109-017-1590-9","volume":"95","author":"E Andreucci","year":"2017","unstructured":"Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J, Bianchini F, Biagioni A, Supuran C, Calorini L. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med. 2017;95(12):1341\u201353.","journal-title":"J Mol Med"},{"issue":"9","key":"1394_CR17","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","volume":"71","author":"YM Lou","year":"2011","unstructured":"Lou YM, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Keller UAD, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT, Dedhar S. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364\u201376.","journal-title":"Cancer Res"},{"issue":"10","key":"1394_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O. Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer. 2017;17(10):577\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1394_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41590-018-0226-8","volume":"19","author":"T Bohn","year":"2018","unstructured":"Bohn T, Rapp S, Luther N, Klein M, Bruehl TJ, Kojima N, Lopez PA, Hahlbrock J, Muth S, Endo S, Pektor S, Brand A, Renner K, Popp V, Gerlach K, Vogel D, Lueckel C, Arnold-Schild D, Pouyssegur J, Kreutz M, Huber M, Koenig J, Weigmann B, Probst HC, von Stebut E, Becker C, Schild H, Schmitt E, Bopp T. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol. 2018;19(12):1319\u201329.","journal-title":"Nat Immunol"},{"issue":"8","key":"1394_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.tips.2017.05.002","volume":"38","author":"GZ Qiu","year":"2017","unstructured":"Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL. Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies. Trends Pharmacol Sci. 2017;38(8):669\u201386.","journal-title":"Trends Pharmacol Sci"},{"key":"1394_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","volume":"164","author":"C Wigerup","year":"2016","unstructured":"Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016;164:152\u201369.","journal-title":"Pharmacol Ther"},{"issue":"14","key":"1394_CR22","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.7150\/jca.52993","volume":"12","author":"WK Xiao","year":"2021","unstructured":"Xiao WK, Zhang GC, Chen B, Chen XQ, Wen LZ, Lai JG, Li XR, Li M, Liu H, Liu J, Han HZ, Lizaso A, Liao N. Mutational landscape of PI3K-AKT-mTOR pathway in breast cancer: implications for targeted therapeutics. J Cancer. 2021;12(14):4408\u201317.","journal-title":"J Cancer"},{"issue":"9","key":"1394_CR23","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1172\/JCI67230","volume":"123","author":"GL Semenza","year":"2013","unstructured":"Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664\u201371.","journal-title":"J Clin Invest"},{"issue":"28","key":"1394_CR24","doi-asserted-by":"publisher","first-page":"20534","DOI":"10.1074\/jbc.M611782200","volume":"282","author":"SC Land","year":"2007","unstructured":"Land SC, Tee AR. Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282(28):20534\u201343.","journal-title":"J Biol Chem"},{"issue":"12","key":"1394_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1394_CR26","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960\u201376.","journal-title":"Cell"},{"issue":"3","key":"1394_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011;1(3):248\u201359.","journal-title":"Cancer Discov"},{"key":"1394_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","volume":"59","author":"AK Murugan","year":"2019","unstructured":"Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92\u2013111.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1394_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11523-017-0482-9","volume":"12","author":"TM Wise-Draper","year":"2017","unstructured":"Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O\u2019Gara S, Olowokure O, Fathallah HA. Phase Ib study of the dual PI3K\/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target Oncol. 2017;12(3):323\u201332.","journal-title":"Target Oncol"},{"issue":"1","key":"1394_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cell.2018.05.009","volume":"174","author":"ZE Walton","year":"2018","unstructured":"Walton ZE, Patel CH, Brooks RC, Yu YJ, Ibrahim-Hashim A, Riddle M, Porcu A, Jiang TY, Ecker BL, Tameire F, Koumenis C, Weeraratna AT, Welsh DK, Gillies R, Alwine JC, Zhang L, Powell JD, Dang CV. Acid suspends the circadian clock in hypoxia through inhibition of mTOR. Cell. 2018;174(1):72\u201387.","journal-title":"Cell"},{"issue":"42","key":"1394_CR31","doi-asserted-by":"publisher","first-page":"18556","DOI":"10.1002\/anie.202005362","volume":"59","author":"Q Cao","year":"2020","unstructured":"Cao Q, Zhou DJ, Pan ZY, Yang GG, Zhang H, Ji LN, Mao ZW. CAIXplatins: highly potent platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors. Angew Chem Int Ed. 2020;59(42):18556\u201362.","journal-title":"Angew Chem Int Ed"},{"issue":"9","key":"1394_CR32","doi-asserted-by":"publisher","first-page":"eaax0937","DOI":"10.1126\/sciadv.aax0937","volume":"5","author":"JY Li","year":"2019","unstructured":"Li JY, Shi KJ, Sabet ZF, Fu WJ, Zhou H, Xu SX, Liu T, You M, Cao MJ, Xu MZ, Cui XJ, Hu B, Liu Y, Chen CY. New power of self-assembling carbonic anhydrase inhibitor: short peptide-constructed nanofibers inspire hypoxic cancer therapy. Sci Adv. 2019;5(9):eaax0937.","journal-title":"Sci Adv"},{"issue":"6","key":"1394_CR33","doi-asserted-by":"publisher","first-page":"1908365","DOI":"10.1002\/adfm.201908365","volume":"30","author":"XY Chen","year":"2020","unstructured":"Chen XY, Zhang HL, Zhang M, Zhao PR, Song RX, Gong T, Liu YY, He XH, Zhao KL, Bu WB. Amorphous Fe-based nanoagents for self-enhanced chemodynamic therapy by re-establishing tumor acidosis. Adv Funct Mater. 2020;30(6):1908365.","journal-title":"Adv Funct Mater"},{"issue":"22","key":"1394_CR34","doi-asserted-by":"publisher","first-page":"8065","DOI":"10.1039\/D0CS00215A","volume":"49","author":"ZJ Xie","year":"2020","unstructured":"Xie ZJ, Fan TJ, An J, Choi W, Duo YH, Ge YQ, Zhang B, Nie GH, Xie N, Zheng TT, Chen Y, Zhang H, Kim JS. Emerging combination strategies with phototherapy in cancer nanomedicine. Chem Soc Rev. 2020;49(22):8065\u201387.","journal-title":"Chem Soc Rev"},{"issue":"52","key":"1394_CR35","doi-asserted-by":"publisher","first-page":"1904997","DOI":"10.1002\/adma.201904997","volume":"31","author":"L Chen","year":"2019","unstructured":"Chen L, Zhou LL, Wang CH, Han Y, Lu YL, Liu J, Hu XC, Yao TM, Lin Y, Liang SJ, Shi S, Dong CY. Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv Mater. 2019;31(52):1904997.","journal-title":"Adv Mater"},{"issue":"34","key":"1394_CR36","doi-asserted-by":"publisher","first-page":"2002661","DOI":"10.1002\/adma.202002661","volume":"32","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xu C, Yang XL, Pu KY. Photoactivatable protherapeutic nanomedicine for cancer. Adv Mater. 2020;32(34):2002661.","journal-title":"Adv Mater"},{"key":"1394_CR37","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1021\/jacs.1c07479","volume":"143","author":"YY Zhao","year":"2021","unstructured":"Zhao YY, Zhang L, Chen ZX, Zheng BY, Ke MR, Li XS, Huang JD. Nanostructured phthalocyanine assemblies with efficient synergistic effect of type I photoreaction and photothermal action to overcome tumor hypoxia in photodynamic therapy. J Am Chem Soc. 2021;143:13980\u20139.","journal-title":"J Am Chem Soc"},{"key":"1394_CR38","doi-asserted-by":"publisher","first-page":"9885","DOI":"10.1002\/anie.201806551","volume":"57","author":"XS Li","year":"2018","unstructured":"Li XS, Lee DY, Huang JD, Yoon JY. Phthalocyanine-assembled nanodots as photosensitizers for highly efficient type I photoreactions in photodynamic therapy. Angew Chem Int Ed. 2018;57:9885\u201390.","journal-title":"Angew Chem Int Ed"},{"issue":"1\u20132","key":"1394_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10555-018-09777-y","volume":"38","author":"O Thews","year":"2019","unstructured":"Thews O, Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev. 2019;38(1\u20132):113\u201329.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1394_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cmet.2019.04.003","volume":"30","author":"S Kumar","year":"2019","unstructured":"Kumar S, Sharife H, Kreisel T, Mogilevsky M, Bar-Lev L, Grunewald M, Aizenshtein E, Karni R, Paldor I, Shlomi T, Keshet E. Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity. Cell Metab. 2019;30(1):201\u201311.","journal-title":"Cell Metab"},{"key":"1394_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.biomaterials.2019.02.014","volume":"201","author":"Xueke Sun","year":"2019","unstructured":"Sun X, Sun B, Dong G, Huang L, Zhang W, Zhou J, et al. Noninvasive temperature monitoring for dual-modal tumor therapy based on lanthanide-doped up-conversion nanocomposites. Biomaterials. 2019;201:42\u201352. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.02.014.","journal-title":"Biomaterials"},{"issue":"21","key":"1394_CR42","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1039\/D1SC01125A","volume":"12","author":"N Kwon","year":"2021","unstructured":"Kwon N, Kim H, Li XS, Yoon JY. Supramolecular agents for combination of photodynamic therapy and other treatments. Chem Sci. 2021;12(21):7248\u201368.","journal-title":"Chem Sci"},{"issue":"36","key":"1394_CR43","doi-asserted-by":"publisher","first-page":"11522","DOI":"10.1002\/anie.201805138","volume":"57","author":"XS Li","year":"2018","unstructured":"Li XS, Kwon N, Guo T, Liu Z, Yoon JY. Innovative strategies for hypoxic-tumor photodynamic therapy. Angew Chem Int Ed. 2018;57(36):11522\u201331.","journal-title":"Angew Chem Int Ed"},{"issue":"11","key":"1394_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41571-020-0410-2","volume":"17","author":"XS Li","year":"2020","unstructured":"Li XS, Lovell JF, Yoon JY, Chen XY. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17(11):657\u201374.","journal-title":"Nat Rev Clin Oncol"},{"issue":"45","key":"1394_CR45","doi-asserted-by":"publisher","first-page":"12269","DOI":"10.1039\/D0SC04486E","volume":"11","author":"SL Mei","year":"2020","unstructured":"Mei SL, Xu XH, Priestley RD, Lu Y. Polydopamine-based nanoreactors: synthesis and applications in bioscience and energy materials. Chem Sci. 2020;11(45):12269\u201381.","journal-title":"Chem Sci"},{"key":"1394_CR46","doi-asserted-by":"publisher","first-page":"119761","DOI":"10.1016\/j.biomaterials.2020.119761","volume":"234","author":"J An","year":"2020","unstructured":"An J, Hu YG, Cheng K, Li C, Hou XL, Wang GL, Zhang XS, Liu B, Zhao YD, Zhang MZ. ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic therapy. Biomaterials. 2020;234:119761.","journal-title":"Biomaterials"},{"key":"1394_CR47","doi-asserted-by":"publisher","first-page":"2007051","DOI":"10.1002\/smll.202007051","volume":"17","author":"WR Zhao","year":"2021","unstructured":"Zhao WR, Hu XC, Zhou LL, Qiang SF, Shi S, Dong CY, et al. M2-like TAMs function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy. Small. 2021;17:2007051.","journal-title":"Small"},{"key":"1394_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.actbio.2016.10.010","volume":"47","author":"YY Li","year":"2017","unstructured":"Li YY, Jiang CH, Zhang DW, Chen XS, Lu LH, et al. Targeted polydopamine nanoparticles enable photoacoustic imaging guided chemo-photothermal synergistic therapy of tumor. Acta Biomater. 2017;47:124\u201334.","journal-title":"Acta Biomater"},{"key":"1394_CR49","doi-asserted-by":"publisher","first-page":"124494","DOI":"10.1016\/j.cej.2020.124494","volume":"389","author":"WW Zheng","year":"2020","unstructured":"Zheng WW, Zhang HJ, Deng YM, Ji XY, Zeng XW, et al. Dual-response oxygen-generating MnO2 nanoparticles with polydopamine modification for combined photothermal-photodynamic therapy. Chem Eng J. 2020;389:124494.","journal-title":"Chem Eng J"},{"issue":"2","key":"1394_CR50","first-page":"1342","volume":"13","author":"Q Huang","year":"2019","unstructured":"Huang Q, Zhang SH, Li Z, Gao MY, et al. Boosting the radiosensitizing and photothermal performance of Cu2-xSe nanocrystals for synergetic radiophotothermal therapy of orthotopic breast cancer. ACS Nano. 2019;13(2):1342\u201353.","journal-title":"ACS Nano"},{"issue":"5","key":"1394_CR51","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","volume":"73","author":"V Estrella","year":"2013","unstructured":"Estrella V, Chen TA, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524\u201335.","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"1394_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10555-019-09792-7","volume":"38","author":"SR Pillai","year":"2019","unstructured":"Pillai SR, Damaghi M, Marunaka Y, Spugnini EP, Fais S, Gillies RJ. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev. 2019;38(1\u20132):205\u201322.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"1394_CR53","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.4161\/cbt.21144","volume":"13","author":"J Karar","year":"2012","unstructured":"Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A. Dual PI3K\/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1 alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther. 2012;13(11):1102\u201311.","journal-title":"Cancer Biol Ther"},{"key":"1394_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fonc.2017.00286","volume":"7","author":"L Iommarini","year":"2017","unstructured":"Iommarini L, Porcelli AM, Gasparre G, Kurelac I. Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Front Oncol. 2017;7:286.","journal-title":"Front Oncol"},{"issue":"5","key":"1394_CR55","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W. HIF-1 alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378\u201389.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"1394_CR56","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ncb3330","volume":"18","author":"EL LaGory","year":"2016","unstructured":"LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol. 2016;18(4):356\u201365.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1394_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.trecan.2019.11.009","volume":"6","author":"S McGuirk","year":"2020","unstructured":"McGuirk S, Audet-Delage Y, St-Pierre J. Metabolic fitness and plasticity in cancer progression. Trends Cancer. 2020;6(1):49\u201361.","journal-title":"Trends Cancer"},{"issue":"6","key":"1394_CR58","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1634\/theoncologist.2017-0343","volume":"23","author":"RH Alvarez","year":"2018","unstructured":"Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM. Emerging perspectives on mTOR inhibitor-associated pneumonitis in breast cancer. Oncologist. 2018;23(6):660\u20139.","journal-title":"Oncologist"},{"issue":"1","key":"1394_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41565-020-00817-9","volume":"16","author":"W Jiang","year":"2021","unstructured":"Jiang W, Wang YF, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021;16(1):6\u201315.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"1394_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273\u201391.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01394-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01394-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01394-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:07:35Z","timestamp":1649768855000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01394-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01394-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out with full authorization approved by the ethical committee for animal care of School of Medicine, Tongji University (Approval No. TJBB00721103).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}